NKTR
Nektar Therapeutics
NASDAQ · Healthcare · Biotechnology · US
$74.19
−2.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 54.6M | 55.2M | 98.4M | 90.1M | 92.1M |
| Cost of Revenue | 347.0K | — | 30.7M | 36.6M | 21.6M |
| Gross Profit | 54.2M | 55.2M | 67.7M | 53.5M | 70.4M |
| Operating Expenses | |||||
| R&D Expense | 131.8M | 117.3M | 120.9M | 114.2M | 218.3M |
| SG&A Expense | 53.3M | 68.7M | 76.8M | 77.4M | 92.3M |
| General & Admin Expense | 53.5M | 68.7M | 76.8M | 77.4M | 92.3M |
| Selling & Marketing Expense | (151.0K) | — | — | — | — |
| Other Expenses | 382.0K | — | (24.7M) | (676.0K) | — |
| Total Operating Expenses | 185.5M | 186.0M | 172.9M | 190.9M | 310.7M |
| Cost and Expenses | 185.8M | 186.0M | 203.6M | 227.5M | 332.3M |
| Operating Income (EBIT) | (131.2M) | (130.8M) | (105.2M) | (137.4M) | (240.2M) |
| Non-Operating | |||||
| Interest Income | 19.2M | 10.4M | 14.5M | 19.0M | 6.8M |
| Interest Expense | 31.0M | 26.2M | 28.1M | 25.3M | 28.9M |
| Net Interest Income | (11.8M) | (15.7M) | (13.6M) | (6.3M) | (22.1M) |
| Other Non-Op Income/Expense | (25.5M) | (33.4M) | (14.0M) | (138.8M) | (124.7M) |
| Non-Operating Income (excl Interest) | 3.6M | 7.3M | (14.1M) | 113.5M | 95.8M |
| EBT (Pre-Tax Income) | (156.7M) | (164.2M) | (119.2M) | (276.3M) | (365.0M) |
| Income Tax Expense | 64.0K | (138.0K) | (239.0K) | (200.0K) | 3.2M |
| Bottom Line | |||||
| Net Income | (157.1M) | (164.1M) | (119.0M) | (276.1M) | (368.2M) |
| Earnings from Cont. Ops | (156.8M) | (164.1M) | (119.0M) | (276.1M) | (368.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (157.1M) | (164.1M) | (119.0M) | (276.1M) | (368.2M) |
| Per Share | |||||
| Basic EPS | ($6.70) | ($9.73) | ($8.68) | ($21.79) | ($29.51) |
| Diluted EPS | ($6.70) | ($9.73) | ($8.68) | ($21.79) | ($29.51) |
| Revenue Per Share | $1.65 | $3.27 | $7.18 | $7.11 | $7.38 |
| Shares | |||||
| Basic Shares Outstanding | 33.1M | 16.9M | 13.7M | 12.7M | 12.5M |
| Diluted Shares Outstanding | 33.1M | 16.9M | 13.7M | 12.7M | 12.5M |
| Profitability Metrics | |||||
| EBITDA | (134.4M) | (137.0M) | (86.7M) | (243.1M) | (323.9M) |
| D&A | 537.0K | 1.0M | 4.4M | 7.8M | 12.2M |
| EBIT | (134.9M) | (138.0M) | (91.1M) | (250.9M) | (336.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026